Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly- l -Lactic Acid Coronary Stents
- 15 May 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 125 (19), 2343-2353
- https://doi.org/10.1161/circulationaha.110.000901
Abstract
Background—: The purpose of this study was to evaluate the long-term safety of the Igaki-Tamai stent, the first-in-human fully biodegradable coronary stent made of poly- l -lactic acid. Methods and Results—: Between September 1998 and April 2000, 50 patients with 63 lesions were treated electively with 84 Igaki-Tamai stents. Overall clinical follow-up (>10 years) of major adverse cardiac events and rates of scaffold thrombosis was analyzed together with the results of angiography and intravascular ultrasound. Major adverse cardiac events included all-cause death, nonfatal myocardial infarction, and target lesion revascularization/target vessel revascularization. During the overall clinical follow-up period (121±17 months), 2 patients were lost to follow-up. There were 1 cardiac death, 6 noncardiac deaths, and 4 myocardial infarctions. Survival rates free of all-cause death, cardiac death, and major adverse cardiac events at 10 years were 87%, 98%, and 50%, respectively. The cumulative rates of target lesion revascularization (target vessel revascularization) were 16% (16%) at 1 year, 18% (22%) at 5 years, and 28% (38%) at 10 years. Two definite scaffold thromboses (1 subacute, 1 very late) were recorded. The latter case was related to a sirolimus-eluting stent, which was implanted for a lesion proximal to an Igaki-Tamai stent. From the analysis of intravascular ultrasound data, the stent struts mostly disappeared within 3 years. The external elastic membrane area and stent area did not change. Conclusion—: Acceptable major adverse cardiac events and scaffold thrombosis rates without stent recoil and vessel remodeling suggested the long-term safety of the Igaki-Tamai stent.This publication has 24 references indexed in Scilit:
- Longitudinal acoustic properties of poly(lactic acid) and poly(lactic- co -glycolic acid)Biomedical Materials, 2010
- Monitoring In Vivo Absorption of a Drug-Eluting Bioabsorbable Stent With Intravascular Ultrasound-Derived Parameters: A Feasibility StudyJACC: Cardiovascular Interventions, 2010
- Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent ImplantationCirculation, 2009
- Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis A substudy of the ABSORB clinical trialEuroIntervention, 2009
- Late Stent Recoil of the Bioabsorbable Everolimus-Eluting Coronary Stent and its Relationship With Plaque MorphologyJournal of the American College of Cardiology, 2008
- Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort StudyJournal of the American College of Cardiology, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Histopathological findings of new in-stent lesions developed beyond five yearsCatheterization and Cardiovascular Interventions, 2006
- In vivo Variability in Quantitative Coronary Ultrasound and Tissue Characterization Measurements with Mechanical and Phased-array CathetersThe International Journal of Cardiovascular Imaging, 2005
- Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary ArteriesCirculation, 2002